GlassScriptPhysician profile
Peter Kyle Chang
NPI 1619995610
$71,629.63
in general payments reported to CMS, 2019-2025
37 companies · $30K in 2025
The $30K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,092 · 2021: $2,661 · 2022: $3,163 · 2023: $3,468 · 2024: $13K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $16K · Travel and Lodging: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,086.25 |
| Food and Beverage | $15,530.95 |
| Travel and Lodging | $964.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34,892.30 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18,058.00 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $5,377.57 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $2,678.92 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $2,130.76 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $1,290.21 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $885.13 | 2019-2025 | Clenpiq, Rebyota |
| Merck Sharp & Dohme LLC | $880.18 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Ardelyx, INC. | $672.13 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $559.46 | 2021-2025 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $501.08 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $401.16 | 2022-2025 | Dupixent |
| Genzyme Corporation | $382.98 | 2022-2025 | |
| Lilly USA, LLC | $358.47 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $338.88 | 2024-2025 | Voquezna |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $317.49 | 2025 | Rezdiffra |
| Ucb, INC. | $261.51 | 2019-2020 | |
| Shire North American Group INC | $179.03 | 2019 | |
| Braintree Laboratories, INC. | $171.04 | 2019-2023 | Suflave |
| Aimmune Therapeutics, INC. | $166.18 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $132.42 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $124.97 | 2021 | |
| Exact Sciences Corporation | $96.20 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $94.06 | 2019-2025 | |
| Amgen INC. | $93.14 | 2021 | |
| Fresenius Kabi USA, LLC | $83.80 | 2023 | Idacio |
| Ipsen Biopharmaceuticals, INC | $83.74 | 2025 | Iqirvo |
| Celltrion USA INC. | $70.24 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $65.87 | 2020 | |
| Boston Scientific Corporation | $53.68 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $51.97 | 2019-2020 | |
| Allergan, INC. | $40.12 | 2019-2020 | |
| Coopersurgical, INC. | $34.96 | 2020 | |
| Novo Nordisk INC | $28.82 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $28.66 | 2023 | Injectafer |
| Fujifilm Healthcare Americas Corporation | $24.62 | 2021 | |
| Concordia Pharmaceuticals INC. | $19.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.